报价延迟最少15分钟:2025/07/16 07:30 EDT
盘前时段
|
||||
|
4.69 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.53
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-161.50/-1.18
|
|
企业价值
2.52M
|
| 资产负债 |
|
每股账面净值
7.65
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/16 07:30 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |
